Literature DB >> 21402833

Pharmacokinetic profiles of ceftazidime after intravenous administration in patients undergoing automated peritoneal dialysis.

Kiwon Kim1, Young-Hwan Hwang, Han Ro, Yun Kyu Oh, Min-Gul Kim, Kyung-Sang Yu, Kwang-Hee Shin, In-Jin Jang, Sang Goo Shin, Curie Ahn, Kook-Hwan Oh.   

Abstract

The pharmacokinetics (PK) of ceftazidime after intravenous (i.v.) administration during automated peritoneal dialysis (APD) and their dependence on peritoneal membrane transport are the targets of the present study. Eleven patients receiving a single i.v. dose of ceftazidime (15 mg/kg of body weight) (seven males, median [interquatile] age, 59 [36 to 62]) were recruited. Serum and dialysate samples were collected at the beginning, middle, and end of each of the five dwells during a 24-h period, with dwells 1, 2, and 3 using an automated cycler (designated on-cycler) and dwells 4 and 5 being manual exchanges (designated off-cycler), together with urine collection during the same period. Population PK analysis was employed to estimate the PK parameters. Peritoneal equilibration tests were performed for all patients, and correlations between peritoneal clearance (CL(PD)) for ceftazidime and dialysate-to-plasma ratios for creatinine (D/P(cr)) were obtained using the Spearman's product correlation coefficient (ρ). Ceftazidime renal clearance (CL(renal)) was 0.052 ml/min/kg, and CL(PD) was 0.063 ± 0.050 ml/min/kg. CL(PD) for on- and off-cycler were 0.071 and 0.058 ml/min/kg (P = 0.164), respectively. A significant correlation between CL(PD) and D/P(cr) was observed, with one outlier excluded, suggesting that CL(PD) for ceftazidime during APD is dependent upon the peritoneal small-solute transport rate. A model prediction yielded adequate serum and dialysate concentrations of ceftazidime throughout a 24-h period for sensitive organisms (MIC, 8 μg/ml) by either i.v. (at 15 mg/kg) or intraperitoneal (i.p.; at 20 mg/kg) administration during off-cycler dwells. The present study suggests that the i.v. administration of ceftazidime at 15 mg/kg or i.p. administration of ceftazidime at 20 mg/kg during a long dwell every 24 h can be recommended for treating systemic or intraperitoneal infections of APD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402833      PMCID: PMC3101436          DOI: 10.1128/AAC.01543-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Correlation of intraperitoneal antibiotic pharmacokinetics and peritoneal membrane transport characteristics.

Authors:  R J Elwell; G R Bailie; H J Manley
Journal:  Perit Dial Int       Date:  2000 Nov-Dec       Impact factor: 1.756

Review 2.  Peritoneal dialysis.

Authors:  Isaac Teitelbaum; John Burkart
Journal:  Am J Kidney Dis       Date:  2003-11       Impact factor: 8.860

3.  Relation between the antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from respiratory specimens and antimicrobial use density (AUD) from 2005 through 2008.

Authors:  Yasutsugu Fukushima; Fumiya Fukushima; Kuniyoshi Kamiya; Yumeko Hayashi; Masamitsu Tatewaki; Issei Yamada; Hirokuni Hirata; Kumiya Sugiyama; Yoshiki Ishii; Takeshi Fukuda
Journal:  Intern Med       Date:  2010-07-15       Impact factor: 1.271

4.  Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis.

Authors:  S Stea; T Bachelor; M Cooper; P de Souza; K Koenig; W K Bolton
Journal:  J Am Soc Nephrol       Date:  1996-11       Impact factor: 10.121

5.  The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients.

Authors:  M M Pannekeet; A L Imholz; D G Struijk; G C Koomen; M J Langedijk; N Schouten; R de Waart; J Hiralall; R T Krediet
Journal:  Kidney Int       Date:  1995-09       Impact factor: 10.612

6.  Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients.

Authors:  H J Manley; G R Bailie; R Frye; M D McGoldrick
Journal:  Perit Dial Int       Date:  2000 Nov-Dec       Impact factor: 1.756

7.  Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients.

Authors:  H J Manley; G R Bailie; R F Frye; M D McGoldrick
Journal:  Perit Dial Int       Date:  2001 Jul-Aug       Impact factor: 1.756

8.  Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis.

Authors:  Harold J Manley; George R Bailie; Reginald Frye; Lorraine D Hess; M Donald McGoldrick
Journal:  J Am Soc Nephrol       Date:  2000-07       Impact factor: 10.121

9.  Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis.

Authors:  N V Dahl; E F Foote; K M Searson; J L Fein; T Kapoian; C A Steward; R A Sherman
Journal:  Ann Pharmacother       Date:  1998-12       Impact factor: 3.154

10.  Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography.

Authors:  C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

View more
  1 in total

Review 1.  Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter.

Authors:  Sameer Dhingra; Nor Azlina A Rahman; Ed Peile; Motiur Rahman; Massimo Sartelli; Mohamed Azmi Hassali; Tariqul Islam; Salequl Islam; Mainul Haque
Journal:  Front Public Health       Date:  2020-11-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.